Drugs: The General Case

Chapter

Abstract

One must start one’s consideration of the general case approach to nonclinical safety assessment from some fundamental assumptions about the drug under development or to be developed. The first assumption is that the primary intended route of therapeutic administration is oral, as is indeed the case for the vast majority of both existing and new drugs. Most aspects of nonclinical safety assessment do not depend on route, and in later chapters we consider in detail the situations where the use of other routes influences what is done for nonclinical safety assessment, and why.

Keywords

Toxicity Marketing Toxicology Carcinogenicity 

References

  1. Alder, S. and Zbinden, G. (1988) National and International Drug Safety Guidelines, M.T.C. Verlog, Zolheron, SwitzerlandGoogle Scholar
  2. FDA (1971) FDA Introduction to Total Drug Quality, US Government Printing office, Washington, DCGoogle Scholar
  3. Goldenthal, E. (1968) Current View on Safety Evaluation of Drugs, FDA Papers, pp 13–18Google Scholar
  4. ICH (1998) E8: General Considerations for Clinical TrialsGoogle Scholar
  5. ICH (2004) S6: Preclinical Safety Evaluation of Biotechnology Derived PharmaceuticalsGoogle Scholar
  6. ICH (2008) M3 (R2) Non-Clinical Safety Studies for the Conduct of Human Clinical Trials for PharmaceuticalsGoogle Scholar
  7. Mathieu, M. (2000) New Drug Development. A regulatory overview, 5th Ed., Parexrel, Waltham, MAGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Gad Consulting ServicesCaryUSA

Personalised recommendations